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Multidrug-resistant and difﬁcult-to-treat Acinetobacter baumannii may be responsible for nosocomial
infections. The production of carbapenem-hydrolyzing class D b-lactamases (CHDLs) and extended-
spectrum b-lactamase (ESBLs) of the GES type possessing a carbapenemase activity has been increas-
ingly reported worldwide in A. baumannii. The aim of this study was to analyze the resistance mecha-
nisms of two carbapenem resistant A. baumannii clinical isolates recovered in a neonatology center in the
center-east of Tunisia.
Two carbapenem resistant A. baumannii isolates were recovered. The ﬁrst isolate co-harbored the
blaGES-11 ESBL gene and the blaOxA-23 CHDL gene. Analyses of the genetic location indicated that the
blaGES-11 gene was plasmid located (Gr6). However, the blaOxA-23 gene was located on the chromosome.
The second strain had only the blaOxA-23 CHDL gene, which was plasmid located.
This study showed the ﬁrst description of the GES-type b-lactamase in A. baumannii in Tunisia.
1. Introduction
Acinetobacter baumannii is a glucose-non-fermentative Gram
negative coccobacillus that has emerged over the last decade as a
cause of healthcare associated infections with elevated morbidity
and mortality. In addition, community-acquired A. baumannii in-
fections are now reported [1]. Through the acquisition of antibiotic
resistance genes by lateral gene transfer, A. baumannii has an
extraordinary ability to become resistant to almost all antibiotics,
leading to multidrug-resistant isolates [2,3]. The rapid and world-
wide emergence of isolates resistant to carbapenems is now
considered as a signiﬁcant health problem because of limited
therapeutic options.
Carbapenemases found in Acinetobacter spp. may belong to class
A (KPC, GES), to metallo-beta-lactamases ((MBL): IMP, VIM, SIM,
NDM) or to class D (carbapenem-hydrolyzing class D b-lactamases
[CHDLs]), the latter being the most disseminated worldwide [1,2].
As elsewhere [4,5,6], occurrence of carbapenem resistance in
A. baumannii in North Africa has been mainly attributed to the
production of CHDLs, with OXA-23 and OXA-58-like enzymes being
the most prevalent [3,7,8].
The aim of this study was to characterize the mechanisms
responsible for carbapenem resistance in two clinical isolates of
A. baumannii recovered from patients hospitalized in the maternity
and neonatology center of Monastir, Tunisia.
2. Material and methods
2.1. Bacterial isolates
Two clinical isolates of multidrug-resistant A. baumannii, the
Ab453 and the Ab537 were recovered in June 2011 from the ma-
ternity and neonatology center of Monastir, Tunisia. Ab453 was
isolated from an intubation in a female infant suffering from
congenital heart disease (single ventricle) and died after 65 days of
hospitalization. The Ab537 isolatewas recovered from amale infant
suffering from a neonatal respiratory distress.
Isolates were identiﬁed by using the API 20 NE system (bio-
Merieux, Marcy l’Etoile, France) and 16S rRNA gene sequencing, as
described previously [9].
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The rifampin-resistant A. baumannii BM4547was used as host in
conjugation assays. A. baumannii and Klebsiella pneumoniae car-
rying respectively the blaOxA-23 and blaGES-1 genes were used as
reference strains [10,11]. Escherichia coliNCTC 50192 harboring four
plasmids of 154, 66, 48 and 7 kb was used as a size marker.
2.2. Susceptibility testing and screening for MBL production
The antibiotic susceptibility of the A. baumannii isolates was
determined by the disk diffusion method on Muller-Hinton agar
plates with b-lactam and non-b-lactam antibiotic-containing disks
(Sanoﬁ Diagnostics Pasteur, Marnes-La-Coquette, France). MICs
were determined using Etest strips (AB bioMerieux, La Balme-les-
Grottes, France) and interpreted according to the guidelines of
the Clinical and Laboratory Standards Institute [12]. MBL produc-
tion was evaluated using Etest strips with imipenem and EDTA (AB
Biodisk, Solna, Sweden) and conﬁrmed by UV spectrophotometry
[13].
2.3. PCR ampliﬁcation and plasmid typing
Whole-cell DNA of A. baumannii was prepared by suspending
one fresh colony into 100 ml of sterile distilled water and heating at
95 C for 10min. After centrifugation, the supernatant was stored at
4 C before analysis. DNA in supernatant was used as a template
under standard PCR procedure [9] with a series of different sets of
primers. Detection of the known acquired CHDLs (blaOxA-23, blaOxA-
40, and blaOxA-58) [14], class A extended-spectrum b-lactamases
(blaPER, blaVEB, and blaGES) [14,15], MBL (blaIMP, blaVIM, blaSIM,
blaNDM) [16,17] and the intrinsic blaOxA-51-like gene was performed
as previously described [14].
Detection of the ISAba1 element upstream of blaOxA-51 and
blaOxA-23 genes was also performed [9]. In addition Ab453 isolate
and Ab537 isolate were also screened for 16S RNA methylase-
encoding genes production (armA, rmtA, rmtB, rmtC, rmtD, and
npmA), as previously described [18].
The primers used in this study are listed in Table 1.
Plasmid typing was performed using the A. baumannii PCR-
based replicon typing [AB-PBRT] method as described previously
[19]. The PCR products fragments were puriﬁed with QIAquick
column (Qiagen, Courtaboeuf, France) and sequenced with an
Applied Biosystems sequencer (ABI 377). The nucleotide and
deduced amino acid sequences were analyzed and compared to
sequences available over the Internet on the National Center for
Biotechnology Information website (http://www.ncbi.nlm.nih.gov/
BLAST/).
2.4. Transfer of b-lactam resistance
Conjugation assays were performed with A. baumannii BM4547
as recipient strain. Brieﬂy, one colony of each of the donor and
recipient strains was cultured separately under weak agitation in
1 ml trypticase soy broth at 37 C, and they were then used in the
mating-out assays. Conjugation was done by incubating 800 ml of
the recipient strain with 200 ml of the donor strain under low
agitation at 37 C for an additional 3 h step. The A. baumannii
transconjugants were selected on trypticase soy agar plates con-
taining ticarcillin (60 mg/ml) and rifampin (50 mg/ml).
2.5. Plasmid extraction and hybridization
Plasmid DNA was extracted by using Kieser method [20] and
analyzed by electrophoresis on a 0.7% agarose gel. Southern
transfer of the plasmid extract was carried out on a nylon mem-
brane (Hybond Nþ; Amersham Pharmacia Biotech. Orsay, France),
as described previously [21]. The membrane was hybridized with a
probe speciﬁc for blaGES (860 bp) gene and for blaOxA-23 (840 bp).
Southern hybridization was carried out as described by the
manufacturer using the ECL non-radioactive labeling and detection
kit (Amersham Pharmacia Biotech).
2.6. PFGE
Ab453 and Ab537 were typed by using ApaI macrorestriction
analyses and pulsed-ﬁeld gel electrophoresis (PFGE) according to
the manufacturer's recommendations (Bio-Rad, Marnes-la-
Coquette, France). Electrophoresis was performed on an agarose
gel using a CHEF-DR II apparatus (Bio-Rad) [14].
3. Results
In 2011, 125 non-repetitive microbial isolates were recovered
from neonates at the maternity and neonatology center of
Monastir, Tunisia; among them 46 (36.8%) weremultidrug resistant
(resistance to more than three antibiotics) [22]. Eleven (24%) were
identiﬁed as Staphylococcus spp. The other 35 (76%) were Gram-
negative bacilli including 31 Enterobacteriaceae, twice Pseudo-
monas and twice A. baumannii: the Ab453 and the Ab537 which
were used in this study (Table 2).
Ab453 and Ab537 were resistant to b-lactams (ticarcillin, cef-
tazidime, cefepime, aztreonam, and carbapenems), to amino-
glycosides (amikacin, gentamicin, tobramicin and netilmicin), to
ﬂuoroquinolones, sulfonamides, and tetracyclines. Both of them
showed susceptibility to colistin and rifampin.
Table 1
Primers used in this study.
Gene type Primer Sequences (50 e 30) Ref.
OXA-40 OXA-40 A GTACTAATCAAAGTTGTGAA [14]
OXA-40 B TTCCCCTAACATGAATTTGT
OXA 58 OXA-58A CGATCAGAATGTTCAAGCGC [14]
OXA-58B ACGATTCTCCCCTCTGCGC
OXA-23 OXA-23A GATGTGTCATAGTATTCGTCG [14]
OXA-23B TCACAACAACTAAAAGCACTG
OXA-51 OXA-51A CTAATAATTGATCTACTCAAG [14]
OXA-51A CCAGTGGATGGATGGATAGATTATC
GES-1 GES-1A ATGCGCTTCATTCACGCAC [15]
GES-1B CTATTTGTCCGTGCTCAGG
PER-1 PER-1 ATGAATGTCATTATAAAAGC [15]
PER-1 ATTTGGGCTTAGGGCAGAA
VEB-1 VEB-1 CGACTTCCATTTCCCGATGC [15]
VEB-1 GGACTCTGCAACAAATACGC
NDM NDM-F GGTTTGGCGATCTGGTTTTC [17]
NDM-R CGGAATGGCTCATCACGATC
IMP IMP-A GAAGGYGTTTATGTTCATAC [17]
IMP-B GTAMGTTTCAAGAGTGATGC
VIM VIM2004A GTTTGGTCGCATATCGCAAC [16]
VIM2004B AATGCGCAGCACCAGGATAG
SIM SIM-F TACAAGGGATTCGGCATCG [17]
SIM-R TAATGGCCTGTTCCCATGTG
ISAba1 ISAba1-B CATGTAAACCAATGCTCACC [14]
ArmA ArmA-multiF ATTTTAGATTTTGGTTGTGGC [18]
ArmAmultiR ATCTCAGCTCTATCAATATCG
RmtB RmtB-multiF ACTTTT ACAATCCCTCAATAC [18]
RmtB-multiR AAGTATATAAGTTCTGTTCCG
NpmA NpmA-multi-F GGGCTATCTAATGTGGTG [18]
NpmA-multi-R TTTTTATTTCCGCTTCTTCGT
RmtA RmtA-multiF AAACTATTCCGCATGGTTC [18]
RmtA-totR TCATGTACACAAGCTCTTTCC
RmtC RmtC-multiF CAGGGGTTCCAACAAGT [18]
RmtC-multiR AGAGTATATAGCTTGAACATAAGTAGA
RmtD RmtD-multiF GGAAAAGGACGTGGACA [18]
RmtD-multiR TCCATCGATTCCACAGG
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Results obtained with Etest strips containing imipenem and
EDTA did not reveal any MBL production among the two isolates.
However, hydrolysis assays performed by UV spectrophotometry
revealed both of them as carbapenemase producers.
After PCR and sequencing of the amplicon, Ab453 and Ab537
were found to be harboring blaOxA-66 (a variant of blaOxA-51) and
blaOxA-23. In addition the Ab453 was carrying blaGES-11 gene.
The insertion sequence ISAba1 was detected upstream of the
blaOxA-23 gene in Ab537 isolate.
PCR experiments for the detection of the blaIMP-type, blaVIM-
type and blaSIM-1 gene and for 16S RNA-methylase-encoding genes
gave negative results.
Matting-out assays with A. baumannii BM4547 followed by se-
lection on ticarcillinerifampin containing plates gave different re-
sults for the two isolates (Table 3).
For Ab453, the transconjugant exhibited an ESBL phenotype but
also showed reduced susceptibilities to carbapenems (Table 3) .In
addition the transconjugant were resistant to aminoglycosides
(amikacin, gentamicin, tobramycin and netilmicin), cotrimoxazole,
and sulfonamides. PCR experiments performed for the trans-
conjugant were positive for the blaGES gene and negative for blaOxA-
23 gene. A DNA probe for the blaGES gene, consisting of an 860 bp
PCR fragment, was used for the hybridization experiment. A posi-
tive signal was observed with the Ab453 plasmid DNA with the
blaGES probe; however, no hybridization signal was observed with
the blaOxA-23 probe. The above results conﬁrm the PCR results of the
transconjugant isolate and suggest that blaOxA-23 gene was located
on the chromosome and blaGES-11 gene was located on a plasmid of
about 90 Kb (Fig. 1).
For Ab537, a transconjugant showing resistant to all tested an-
tibiotics was found. After PCR the transconjugant was positive for
blaOxA-23, suggesting its plasmid location, which was conﬁrmed by
hybridization experiment.
AB-PBRT PCR performed for our isolates and their trans-
conjugants revealed that plasmids p (Ab537) (OXA-23) and p
(Ab453) (GES-11) harbored the aci6 replicase gene belonging to
group GR6.
PFGE analysis showed that the two isolates clustered into 2
different PFGE types (data not shown).
4. Discussion
Carbapenem resistance in A. baumannii is most often mediated
by acquired CHDLs (OXA-23-like, OXA-40-like, and OXA-58-like)
and less frequently by MBLs. OXA-type carbapenemases have pre-
dominated in A. baumannii, especially worldwide outbreaks of
OXA-23 [1]. Recently the GES-1-like carbapenemases have also
been reported for A. baumannii [9,14,23,24,25].
In Tunisia, resistance to carbapenem in A. baumannii isolates has
been found to be associated with the production of CHDLs (OXA-97
and OXA-23) [3,7,8]. However, recently Bonnin et al. reported
A. baumannii carrying NDM-1 MBL. The strain was recovered in
France from a Tunisian patient [26].
In our study, two carbapenem-resistant A. baumannii isolates
recovered from two neonates hospitalized in the maternity and
neonatology center of Monastir, Tunisia in June 2011 were resistant
to almost all antibiotics but colistin and rifampin.
Ab453 and Ab537 isolates produced the intrinsic blaOxA-51-like
gene (blaOxA-66) supporting the identiﬁcation of the strains as
A. baumannii [25]. Noteworthy, ISAba1 was detected upstream to
blaOxA-23 gene in Ab537 isolate.
The involvement of OXA-51-like enzymes in carbapenem-
resistance in our stains could be ruled out since ISAba1 was not
detected upstream to blaOxA-66 [26].
For Ab453, association of the blaOxA-23 with ISAba1 could be
responsible for high levels of carbapenem resistance since ISAba1
element may act as a strong promoter and could be responsible for
higher blaOxA-23 expression resulting in a high level of carbapenem
resistance as previously reported [26].
Occurrence of GES-11 among clinical isolates of A. baumannii has
been described for the ﬁrst time in France, the clinical isolate was
harboring both blaOxA-58 and blaGES-11 genes [20]. Since then,
several GES-1 mutants have been detected in A. baumannii, such as
GES-12, GES-14, and GES-22 [9,14,22,23,24].
Table 2
Case history of the two neonates with OXA-23 and/or GES-11 producing Acinetobacter baumannii.
Isolate ref Date of
hospitalization
(mo/day/yr)
Age
(day)
Sex Date of
isolation
(mo/day/yr)
Underlying conditions Site of
isolation
Treatment Outcome
Ab453 04/21/11 1 F 06/17/11 Congenital heart disease Intubation Ceftazidime, amikacin Died (06/25/11)
Ab537 06/08/11 1 M 06/12/11 Infant respiratory distress syndrome Catheter Gentamicin, ceftazidime, ampicillin Improved (06/25/11)
Table 3
b-Lactams MICs for A. baumannii clinical isolates Ab453, the A. baumannii BM4547 (pGES-11) transconjugant, A. baumannii clinical isolates Ab537, the A. baumannii BM4547
(pOXA-23) transconjugant and the A. baumannii BM4547reference strain.
MIC (mg/ml)
A. baumannii Ab453
(GES-11, OXA-23)
A. baumannii BM4547
(pAb453) (GES-11)
A. baumannii
BM4547
A. baumannii AB537
(OXA-23)
A. baumannii BM4547
(pAb537) (OXA-23)
b-lactams
Ticarcillin >256 >256 8 >256 >256
Ticarcillin þCLAa >256 256 8 >256 >256
Piperacillin >256 >256 4 >256 >256
Piperacillin þ TZBa >256 256 4 >256 >256
Cefoxitin >256 >256 256 >256 >256
Cefotaxime >64 >64 >32 64 64
Ceftazidime >64 >64 4 >64 8
Cefepime >64 32 16 >64 >32
Aztreonam >64 64 32 >64 >64
Meropenem 32 2 0.5 >32 >24
Imipenem 32 1 0.25 >32 >24
a CLA, Clavulanic acid (4 mg/ml); TZB, Tazobactam (4 mg/ml).
3
ht
tp
://
do
c.
re
ro
.c
h
DNA sequencing of the blaGES gene identiﬁed in Ab453 gave
100% identity with GES-11. GES-11 b-lactamase possesses increased
activity against aztreonam [14,23]. However the blaGES-11-carrying
transconjugant showed reduced susceptibilities to carbapenems,
suggesting the presence of weak hydrolysis of carbapenems by this
enzyme potentiated by the efﬂux overproduction in A. baumannii
BM4547 [14,23].So, GES-11may contribute to play a synergistic role
toward resistance to carbapenems in A. baumannii, together with
OXA-23 [14].Several studies reported the association between the
blaGES and blaOxA-like gene, especially blaGES-11 and blaOxA-23 genes
[14,23,24]. To our knowledge, however, carbapenem resistant
A. baumannii isolate producing the carbapenem-hydrolyzing oxa-
cillinase OXA-23 in associationwith the GES-11 class A b-lactamase
in Tunisia have not been reported previously.
Plasmid analysis and AB-PBRT PCR showed that both plasmids
(pAb453 and pAB537) were of ca. 90 Kb in size and belonged to the
plasmid group Gr6 which has been shown to be highly prevalent in
A. baumannii strains and was previously found to be associated
with the blaOxA-23, blaOxA-40,,blaOxA-58 CHDL genes and the blaGES-11/
GES-14 genes [2,14,24].
Unfortunately, in the current study, MLST PCR which could be
interesting to compare clonality of our A. baumannii GES-11 pro-
ducing with other GES-type recovered elsewhere was not
performed.
Clinical data presented in Table 2 explain a hypothesis con-
cerning the origin of isolates. The Ab537 was isolated from a
neonate hospitalized the 8 of June 2011 because of a neonatal
respiratory distress after 7 h of birth. He recovered after two days
antibiotics therapy and left the hospital on the 25th of June. The
origin of this strain is internal and concerns the neonatology center.
The Ab453 strain was isolated from a neonate hospitalized in
April 2011 because of heart disease. In June, he was transferred to
another hospital (University hospital Sahloul, Sousse) for an urgent
surgery. He was re-admitted in the neonatology center and
received imipenem and amikacin. Five days after surgery he died.
The blaOxA-23 was previously described in the university hospital
Sahloul in Tunisia [3] and it was chromosome located. However,
numerous other studies showed the plasmid location of the blaOxA-
23 gene [6,24].So, a possible transfer of this strain from the Sahloul
university hospital to the neonatology center is strongly probable.
In conclusion, this study re-emphasizes the worldwide
dissemination of OXA-carbapenemase genes in multidrug-resistant
clinical isolates of A. baumannii and supports our understanding of
carbapenem resistance in A. baumannii strains from Tunisia,
showing that acquisition of blaOxA-23 gene seems to be the most
prevalent mechanism of carbapenem resistance among A. bau-
mannii in Tunisia [3,4].
Emergence of GES-type ESBLs in A. baumannii [9,14,24,25]
highlights the propensity of A. baumannii to acquire new resis-
tance mechanisms and it further underlines the absolute necessity
to control inpatients transferred from hospitals. However the
occurrence of GES enzymes in this species in Tunisia is probably
underestimated, since synergism between extended-spectrum
cephalosporins and clavulanic acid may be masked by the pres-
ence of the intrinsic AmpC cephalosporinase and OXA-51-like
oxacillinase that are frequently associated with other a^-lactamases.
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